SRPK3介导的TPM1可变剪接驱动HFpEF舒张功能障碍
该研究探讨了TPM1可变剪接在射血分数保留的心力衰竭(HFpEF)中的作用。通过电镜、纳米压痕、基因工程小鼠和人类多能干细胞衍生心肌细胞,发现HFpEF中TPM1b亚型(跳过外显子9a)上调,且SRPK3激酶介导该剪接;过表达SRPK3诱导舒张功能障碍,而敲低SRPK3或补充含外显子9a的TPM1可改善表型。结论提示SRPK3是HFpEF的潜在治疗靶点。
要点
- HFpEF患者和小鼠模型中TPM1b亚型(跳过外显子9a)表达上调。
- SRPK3激酶介导TPM1外显子9a的可变剪接,过表达导致舒张功能障碍。
- 敲低SRPK3或补充含外显子9a的TPM1可部分挽救舒张功能障碍。
核心结论
- TPM1外显子9a的可变剪接是HFpEF心肌纤维紊乱和舒张功能障碍的关键致病机制,依赖于上游剪接激酶SRPK3。
- SRPK3可能成为HFpEF的新型治疗靶点。
研究设计与样本
- 使用透射电子显微镜检查HFpEF心肌纤维紊乱,纳米压痕检测心肌顺应性。
- 利用AAV9基因工程小鼠模型和人类多能干细胞衍生心肌细胞研究TPM1亚型及SRPK3的作用。
- 采用RNA pulldown、质谱、剪接分析等分子技术探究机制。
主要发现
- HFpEF患者和小鼠模型中均观察到TPM1b亚型(跳过外显子9a)上调。
- 心肌细胞特异性过表达TPM1b(不含外显子9a)加重小鼠和人类多能干细胞衍生心肌细胞的HFpEF表型。
- SRPK3介导TPM1外显子9a的剪接;过表达SRPK3诱导心肌纤维紊乱和舒张功能障碍,而敲低SRPK3改善这些病理表型。
- 补充含外显子9a的TPM1可部分挽救SRPK3过表达条件下的舒张功能障碍。
- 预防性干预实验表明,失活SRPK3可减轻HFpEF小鼠模型的舒张功能障碍。
临床怎么用
- SRPK3可能作为HFpEF的潜在治疗靶点,未来可探索其抑制剂或调节TPM1剪接的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, a condition characterized by impaired diastolic function and elevated left ventricular stiffness. TPM1 (tropomyosin 1), a crucial part of the thin filament in cardiomyocytes, has multiple alternative exons. However, the impact of TPM1 alternative splicing (AS) in HFpEF remains unclear. METHODS: We examined cardiac myofiber disarray in HFpEF using transmission electron microscopy. Nanoindentation was used to detect myocardial compliance. Using genetically engineered (adenovirus-associated virus serotype 9) mouse models and human pluripotent stem cell-derived cardiomyocytes, we investigated the role of TPM1 isoforms and TPM1's upstream SRPK3 (serine/arginine rich protein kinase 3). Subsequently, the underlying mechanisms were investigated using RNA pulldown, mass spectrometry, AS analysis, and other molecular techniques. RESULTS: We identified unique myofilament disorders in HFpEF and observed upregulation of the TPM1b isoform, which skips exon 9a through AS, in both patients with HFpEF and mouse models. Cardiomyocyte-specific overexpression of distinct TPM1 isoforms showed that TPM1b (without exon 9a) exacerbated HFpEF phenotypes in mice and human pluripotent stem cell-derived cardiomyocytes. Furthermore, we found that the splicing kinase SRPK3 mediates the AS of TPM1 exon 9a. Cardiomyocyte-specific overexpression of SRPK3 induced myofiber disarray and diastolic dysfunction, whereas SRPK3 knockdown ameliorated these pathological phenotypes. Supplementation with TPM1 containing exon 9a partially rescued the diastolic dysfunction under conditions of SRPK3 overexpression. Preventive intervention experiments demonstrated that inactivating SRPK3 can alleviate diastolic dysfunction in the HFpEF mouse model. CONCLUSIONS: AS of TPM1 exon 9a is a critical pathogenic mechanism in myofilament disorder and diastolic dysfunction in HFpEF, which is dependent on the upstream splicing kinase SRPK3. SRPK3 may represent a novel therapeutic target for HFpEF.
引用
- Chen, Wang, Yin, et al. Alternative Splicing of TPM1 Mediated by SRPK3 Drives Cardiac Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation. 2026. PMID: 42261667. doi:10.1161/CIRCULATIONAHA.125.079124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。